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Abstract
Background: Our aim was to estimate the burden of fatal disease attributable to excess adiposity
in England and Wales in 2003 and 2015 and to explore the sensitivity of the estimates to the
assumptions and methods used.
Methods:  A spreadsheet implementation of the World Health Organization's (WHO)
Comparative Risk Assessment (CRA) methodology for continuously distributed exposures was
used. For our base case, adiposity-related risks were assumed to be minimal with a mean (SD) BMI
of 21 (1) Kg m-2. All cause mortality risks for 2015 were taken from the Government Actuary and
alternative compositions by cause derived. Disease-specific relative risks by BMI were taken from
the CRA project and varied in sensitivity analyses.
Results: Under base case methods and assumptions for 2003, approximately 41,000 deaths and a
loss of 1.05 years of life expectancy were attributed to excess adiposity. Seventy-seven percent of
all diabetic deaths, 23% of all ischaemic heart disease deaths and 14% of all cerebrovascular disease
deaths were attributed to excess adiposity. Predictions for 2015 were found to be more sensitive
to assumptions about the future course of mortality risks for diabetes than to variation in the
assumed trend in BMI. On less favourable assumptions the attributable loss of life expectancy in
2015 would rise modestly to 1.28 years.
Conclusion: Excess adiposity appears to contribute materially but modestly to mortality risks in
England and Wales and this contribution is likely to increase in the future. Uncertainty centres on
future trends of associated diseases, especially diabetes. The robustness of these estimates is
limited by the lack of control for correlated risks by stratification and by the empirical uncertainty
surrounding the effects of prolonged excess adiposity beginning in adolescence.
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Background
The increase in adiposity over recent decades is widely
believed to herald substantial adverse effects on health
trends. Robust estimates of these effects are needed to
inform societal responses to this challenge.
Recently, the UK Foresight Programme commissioned
work to model possible future trends in obesity and their
expected health effects [1]. The microsimulation pro-
grams developed for this project hold promise for explor-
ing potential effects on population health through time.
However, the published report provides only limited esti-
mates of incident disease or death attributable to excess
adiposity at the beginning of the 21st century. (Graphical
outputs are given for incident stroke, coronary heart dis-
ease, diabetes and arthritis attributable to BMIs in excess
of 25 (figures 27 to 34) [1]). A summary measure of fatal
effects – reductions in life expectancy at birth – is provided
only for projected increases in adiposity beyond the levels
prevailing in 2000–2004. The program is now publicly
available Tim.Marsh@heartforum.org.uk but its "user-
friendliness" remains to be confirmed.
Here we pursue a complementary path to exploring mor-
tality attributable to excess adiposity in England and
Wales in 2003. We also derive estimates for 2015, under
varying assumptions. We use relatively straightforward
cell-based computations in Excel and the model is pro-
vided as an online appendix.
Levels of adiposity are most commonly measured indi-
rectly by the Body Mass Index (BMI). In estimating disease
burdens attributable to excess adiposity, BMI has typically
been treated as a categorical exposure (employing catego-
ries such as underweight, normal weight, overweight and
obese). The method developed by the global Comparative
Risk Assessment (CRA) project [2] compares aggregated
mortality risks under actual or projected BMI distributions
with the corresponding risks under a "theoretical mini-
mum risk" counterfactual distribution of BMI. The CRA
method respects the continuous nature of BMI distribu-
tions in contrast to methods that treat this exposure as cat-
egorical.
Methods
We estimate mortality attributable to excess adiposity
using Population Attributable Fractions. Conceptually,
the Population Attributable Fraction (PAF) is the fraction
by which the occurrence of a disease of interest would be
reduced under a sustained alternative, more favourable,
exposure distribution. For assessing the full effects of a
given distribution of "exposure" (BMI), the appropriate
comparator (or counterfactual) is a distribution deemed
likely to confer "theoretical minimum risk". For our base
case, we have followed the CRA project in using as a coun-
terfactual a BMI distribution with a mean of 21 Kg m-2 and
a standard deviation of 1 Kg m-2, but this choice can be
varied easily within the model.
Further details on the CRA methodology employed and
its implementation in Excel are given in Additional file 1
and Additional file 2 and from the methodological [3]
and substantive [2] publications of the CRA. (We also pro-
vide the full model with all the associated worksheets as
Additional file 3).
In summary,
These aggregates of population risk can be thought of as
proportional to "areas under the curve", made up, in a dis-
crete approximation, of small strata of proportions
exposed at a given level times the risk at that level, so that
where p1 refers to the factual (or predicted) and p2 to the
counterfactual BMI distribution. In the CRA method, the
RRs for all positions on the counterfactual exposure distri-
bution are set to 1 and given that the sum of the probabil-
ity distribution is 1, the formula simplifies to:
A discrete approximation to a normal distribution is
implemented in Excel using the NORMDIST function.
This enables calculation of the "distance travelled" on the
X (BMI) axis in moving from a given position in the fac-
tual distribution to the corresponding position on the
counterfactual distribution. This quantity times the slope
of logRR on BMI gives the change of logRR and the expo-
nent of this provides the RRi for each stratum of interest.
The products of these RRi's with the proportions exposed
at each level can then be summed across the strata to give
the PAFs, from the formula above. Potential shortcomings
with this approach are considered further in the discus-
sion.
We considered only attributable loss of life from deaths
assigned (by the UK Office for National Statistics (ONS))
to colorectal cancer, breast cancer, cancer of the body of
the uterus, diabetes, hypertensive heart disease, ischaemic
heart disease and cerebrovascular disease – and these
losses are expressed in the metrics of deaths, years of life
PAF
attributable population risk
total population risk
fact
=
=
u ual population risk - counterfactual population risk
factua al population risk
PAF
p1iRRi p2iRRi
p1iRRi
=
−∑ ∑
∑
PAF
p1iRRi
p1iRRi
=
− ∑
∑
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lost (YLL, under varying weighting assumptions) and loss
of life expectancy.
Data sources
Distributions of BMI for 1997 to 2004 were obtained
from the Health Survey for England (HSE) [4]. BMI trends
in this period were projected forward, separately by age
and sex groups to 2015. The "Mainsetup" sheet of the
Excel model allows alternative projected trends in BMI to
be selected. We have explored 3 main alternatives:
i. No change;
ii. A slowing rise – BMI increases by 30% less than the pre-
ceding linear trend;
iii. Extrapolation of the trend for 1997 to 2004.
Mortality and population data are from the Office for
National Statistics [5,6]. Predicted all cause mortality rates
for 2015 (by age and sex) are from the Government Actu-
ary [7]. Two variants of the composition of risks within
this mortality "envelope" are explored:
i. The composition remains constant from 2003–5;
ii. WHO predictions for high income countries are
applied [8];
The CRA method requires as inputs observed associations
between BMI levels and mortality risks for the causes of
interest. We have taken these (in the form of slopes of
logRR on BMI) from the meta-analyses performed for the
CRA project [9]. No deaths under 30 have been attributed
to excess adiposity.
Estimation of attributable mortality
We considered only attributable loss of life from deaths
assigned (by the UK Office for National Statistics (ONS))
to colorectal cancer, breast cancer, cancer of the body of
the uterus, diabetes, hypertensive heart disease, ischaemic
heart disease and cerebrovascular disease – and these
losses are expressed in the metrics of deaths, years of life
lost (YLL, under varying weighting assumptions) and loss
of life expectancy.
The years of life lost as a result of death at a given age can
be assigned on varying assumptions. We have incorpo-
rated 3 alternative user-selectable systems for deriving YLL
weights:
i. The reference life tables used in the Global Burden of
Disease and CRA projects. These have a life expectancy at
birth of 80 years for males and 82.5 years for females;
ii. UK period life tables. Use of these would assign (as
YLL) the expected number of years of life remaining under
the current (period) UK life table at the age of death;
iii. The absolute time remaining to age 75, otherwise
known as 'Person Years of Life Lost to Age 75 (PYLL75) –
a metric used by the UK Office for National Statistics.
The streams of life lost under each of these systems may,
optionally, be discounted at 3% per year and/or age-
weighted (using the GBD age weights). We have followed
the GBD convention in using both discounting and age-
weighting [10] for the YLL estimations presented here.
The setup page of the workbook provides a graphical dis-
play of the YLL weighting system chosen by the user
selected inputs.
The attributable loss of life expectancy is calculated by
subtracting mortality risks attributable to higher than
optimal BMI from the overall mortality rates, using estab-
lished methods [11].
Results
BMI distributions
In 2003, the mean BMI in England and Wales for persons
30 or older was 27.7 Kg m-2 for males and 27.3 Kg m-2 for
females. If BMI levels increase linearly, they would rise by
2015 to 29.1 Kg m-2 and 28.4 Kg m-2 for males and
females respectively (assuming constant age structure).
Attributable mortality in 2003
In 2003 the estimated attributable reduction in life expect-
ancy was 1.05 years. There were approximately 41,000
attributable deaths. The years of life lost per attributable
death average 12.4 using a period life table for England
and Wales without discounting or age-weighting the
streams of lost life. Using the GBD YLL metric (reference
life table, with discounting and age-weighting) this was
reduced to 6.4 years (Table 1). Males accounted for 52%
of attributable deaths and 60% of YLL. The leading causes
of attributable deaths were ischaemic heart disease (55%),
cerebrovascular disease (20%) and diabetes (9%) (Figure
1).
The 41,000 deaths attributed to higher than optimal BMI
in 2003 amounted to around 9% of all deaths in England
and Wales. This included 77% of all diabetic deaths, 23%
of all ischaemic heart disease deaths and 14% of all cere-
brovascular disease deaths.
Projections for 2015
The effect of varying assumptions about the future trend
of BMI turned out to be surprisingly modest: increasing
the attributable loss of life expectancy in 2015 from 1.04
years for both sexes combined in the case of no furtherPopulation Health Metrics 2009, 7:11 http://www.pophealthmetrics.com/content/7/1/11
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increase in BMI to 1.16 years – if the recent increase in
mean BMI is projected forward (both estimates assuming
a constant composition of mortality risks).
Predicted losses of longevity were somewhat more sensi-
tive to assumptions about changes in the composition of
mortality risks by 2015 – with the predicted course of dia-
betes risks holding the key. This is illustrated by the black
sections of the bars in Figure 1 which show the increase in
attributable deaths implied by an increased share of dia-
betes in overall mortality risks, as entailed in the WHO
mortality projections. In Figure 1 these outweigh the effect
of declining total (attributable and non-attributable)
mortality risks from ischaemic heart disease.
Uncertainty over the future course of diabetes risk can be
illustrated further with predictions for males aged 60 to
70. An extrapolation of recent trends in the proportion of
deaths at this age assigned to diabetes would see the
number of deaths from this cause in 2015 increase from
318 to 431 (in this age group). The WHO predictions,
however, imply a much sharper increase – to 1318 deaths
per year.
Under the least favourable scenario for 2015 – with con-
tinuing increases in mean BMI and a (not unrelated)
sharp rise in the proportion of deaths from diabetes – the
attributable loss of life expectancy is 1.28 years for both
sexes combined.
Discussion
Our base case results are broadly consistent with findings
from other studies using similar methodology for the esti-
mation of population attributable fractions. Our estimate
of 41,000 attributable deaths (9% of all deaths) per year
in England and Wales between 2003 and 2005 bears com-
parison with the National Audit Office's (NAO)[12] esti-
mate of over 31,000 deaths per year attributable to
"obesity" in England in 1998, when BMI levels were
lower. Banegas et al. [13] estimated that 8.7% of all deaths
in the UK were attributable to excess adiposity, which is
very close to our own estimate. Using a similar methodol-
ogy, Ni Mhurchu et al. [14] estimated 11% of all deaths in
New Zealand for the year 1997 were attributable to excess
adiposity. This amounted to 83% of all diabetes deaths,
24% of all ischaemic heart disease deaths and 15% of
ischaemic stroke deaths. Ni Mhurchu et al. also found that
higher-than optimal BMI was most prevalent in the 55–64
years old age group, as opposed to the slightly older age
group of 60–69 years of age of our own estimates.
We have compared our cause-specific effect estimates with
those of the Prospective Studies Collaboration (PSC)
analyses of results from 900,000 subjects [15]. The incre-
ments of risk per unit of BMI that are employed here lie
close to and on either side of the values in Table 2 of the
PSC report. Exact comparison is precluded as the PSC
slopes begin at BMI 25 kgm-2whereas the existing CRA
slopes extend down to the counterfactual mean of BMI =
21 kgm-2. The comparability of the exposure risk slopes
also addresses the issue that the CRA implementation
(which we have employed) uses slopes of incidence on
exposure which could, in principle, be biased as proxies
for mortality on exposure. The PSC however reports on
the metrics of mortality.
Potential biases in the methods employed
There are a number of potential sources of bias in meth-
ods employed. Firstly, our method may yield biased esti-
mates when used with relative risks adjusted for
confounding. This occurs when adiposity is correlated
with other exposures or unobserved factors in the popula-
tion of interest, resulting in under- (when there is a posi-
tive correlation) or over- (negative correlation) estimation
of the true PAF when used with adjusted relative risks [16-
18]. However, the information requirements of con-
founder adjusted methods effectively preclude their use
here. Flegal et al. have illustrated the potential magnitude
of the biases associated with different analytic methods
[18] and recommend the use of sensitivity analyses.
Potential confounding by smoking has been a concern in
this field, but the PSC analyses found virtually identical
slopes of risk on exposure for never smokers and current
smokers (Figure 6, [15]).
Deaths from 5 causes of interest, by whether attributable to  excess adiposity, England and Wales, 2003 (left columns) and  2015 (right columns) Figure 1
Deaths from 5 causes of interest, by whether attrib-
utable to excess adiposity, England and Wales, 2003 
(left columns) and 2015 (right columns). All cause mor-
tality levels in 2015 as predicted by the Government Actuary, 
composition of mortality risks as predicted by WHO for 
high-income countries.
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Secondly, the methods used here are based on risks
observed in subjects mostly recruited and measured in
middle age in the 1980s and 90s. The cohorts currently in
middle and late middle age will typically have gained adi-
posity at an earlier age and this may confer risks addi-
tional to those considered here. Adiposity in adolescence
appears to be strongly predictive of later risk [19,20], but
studies that relate risk to measures of exposure integrated
over the lifespan are apparently few.
In addition, causes other than those examined in our
study may be positively associated with excess adiposity,
which biases our estimates of attributable deaths down-
ward.
Predictions
The Foresight model predicted that the increase in adipos-
ity between 2004 and 2015 would reduce life expectancy
by about 0.11 years in men and 0.02 years in women (Fig-
Table 1: Mortality attributable to excess adiposity: deaths, YLL, PYLL75 and loss of life expectancy – total population, males and 
females, England and Wales, 2003 and 2015.
2003 2015 – composition of mortality risks same as in 
2003–05
2015 – composition of mortality risks from WHO 
prediction for high-income countries
No change
in BMI
BMI increase
30% below
recent trend
BMI increase
continues
recent trend
No change
in BMI
BMI increase
30% below
recent trend
BMI increase
continues
recent trend
Total 
population
Attributable 
deaths
40,874 40,613 44,914 46,540 46,703 51,140 52,798
Years of life lost 
(YLL*)
261,15
3
254,862 275,618 283,591 280,594 300,364 307,941
YLL* per 
attributable death
6.39 6.28 6.14 6.09 6.01 5.87 5.83
PYLL75 134,80
5
136,866 147,023 150,615 145,220 154,202 157,337
Attributable loss 
of life expectancy 
(years)
1.05 1.04 1.13 1.16 1.16 1.25 1.28
Males
Attributable 
deaths
21,250 20,072 22,869 23,897 22,133 24,937 25,944
Years of life lost 
(YLL*)
155,51
9
144,071 158,015 163,318 146,431 159,155 163,949
YLL* per 
attributable death
7.32 7.18 6.91 6.83 6.62 6.38 6.32
PYLL75 92,008 87,223 94,655 97,386 84,761 91,159 163,949
Attributable loss 
of life expectancy 
(years)
1.19 1.12 1.24 1.28 1.18 1.30 1.34
Females
Attributable 
deaths
19,625 20,541 22,044 22,643 24,570 26,203 26,854
Years of life lost 
(YLL*)
105,63
4
110,791 117,603 120,273 134,163 141,209 143,992
YLL* per 
attributable death
5.38 5.39 5.33 5.31 5.46 5.39 5.36
PYLL75 42,797 49,642 52,369 53,229 60,459 63,043 63,839
Attributable loss 
of life expectancy 
(years)
0.92 0.96 1.02 1.04 1.14 1.20 1.23
* YLL weights use GBD reference life tables, 3% discounting and age-weighting.
All cause mortality levels in 2015 from Government Actuary's predictions, with composition of mortality risks assumed constant or as predicted by 
WHO for high-income countries.Population Health Metrics 2009, 7:11 http://www.pophealthmetrics.com/content/7/1/11
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ure 18 of their report)[1]. This is comparable with our
own projection for this period, with reduction of 0.28
years (derived from the model). These estimates, based on
very different methodologies, suggest relatively minor
effects on life expectancy from rising adiposity. Much of
the reason is that the leading cause of death whose risk is
increased by adiposity (ischaemic heart disease) is pro-
jected, for other reasons, to decline as a proportion of
total mortality risks. This assumption may not be robust.
We have sought to contain the uncertainty arising from
interdependent trends in adiposity and related mortality
risks by using the Government Actuary's predictions for
2015 to define an all cause mortality "envelope" within
which the sum of specific causes of death is constrained to
fit. This (arbitrarily) restrains uncertainty to the propor-
tions of deaths likely to be from each cause. A defence of
this approach is that official projections of all cause mor-
tality, such as those of the Government Actuary, have an
unbroken record of conservatism: things have (so far)
invariably turned out better than expected [21]. There can,
however, be no guarantee that that this will continue to be
so in the future.
Conclusion
Excess adiposity appears to contribute materially but
modestly to mortality risks in England and Wales and this
contribution is likely to increase in the future. The robust-
ness of these estimates is limited by the lack of control for
correlated risks by stratification and by the empirical
uncertainty surrounding the effects of prolonged excess
adiposity beginning in adolescence.
Work to reduce uncertainty in predictions like these needs
to concentrate on the mutual relationships between evolv-
ing levels of adiposity and the composition of mortality
risks in the short to medium term future. It is not easy to
model such interdependent trajectories in Excel. Micro-
simulation methods, as used in the Foresight report, may
have a useful role in modelling such trajectories. Cell-
based methods like ours and microsimulation methods
could thus continue to play complementary roles. Both
will remain dependent on the quality of epidemiological
data mapping these evolving epidemics.
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